Author + information
- Received December 21, 1994
- Revision received May 16, 1995
- Accepted May 24, 1995
- Published online October 1, 1995.
- Stefan H. Hohnloser, MD, FACC*,
- Andreas van de Loo, MD and
- Frank Baedeker, MD
Objectives. This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation.
Background. Atrial fibrillation is the most common arrhythmia. Pharmacologic therapy has been advocated for both immediate restoration of sinus rhythm and prevention of recurrent atrial fibrillation. Quinidine is the therapeutic mainstay for both purposes, but its safety has recently been questioned. Although sotalol has been used successfully to maintain sinus rhythm after direct current cardioversion, its efficacy in pharmacologically reverting atrial fibrillation has not been examined.
Methods. Fifty consecutive patients with persistent atrial fibrillation were randomized to receive quinidine or sotalol for up to 7 days to restore sinus rhythm. Patients were followed up for 6 months.
Results. Quinidine was more effective than sotalol in terminating atrial fibrillation (60% vs. 20%, p = 0.009). When nonresponders to drug therapy underwent subsequent direct current cardioversion, total conversion rates in the quinidine and sotalol groups were comparable (88% vs. 68%, p = 0.17), as was the efficacy of the two drugs in preventing recurrent atrial fibrillation. Side effects necessitating drug discontinuation were more often observed with quinidine. No patient receiving sotalol but four patients receiving quinidine had drug-associated arrhythmia (torsade de pointes in three patients, sustained ventricular tachycardia in one patient). Precordial QT dispersion determined on the surface electrocardiogram (ECG) increased with quinidine (mean ± SD 34 ± 9 vs. 44 ± 16 ms, p = 0.02), indicating enhanced inhomogeneity in ventricular repolarization. There was no change in QT dispersion in patients receiving sotalol (36 ± 18 vs. 40 ± 17 ms, p = 0.44).
Conclusions. Quinidine is more effective than sotalol in terminating atrial fibrillation but is associated with more side effects. The proarrhythmic risk may be related to quinidine's propensity to increase disparity in ventricular repolarization. This risk warrants careful ECG monitoring during the 1st 4 to 7 days of therapy. Because most proarrhythmic effects occurred shortly after restoration of sinus rhythm, observation should continue ≥2 to 3 days after sinus rhythm is reestablished.
↵* Present address and address for correspondence:Dr. Stefan H. Hohnloser, Department of Medicine, Division of Cardiology, J. W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt. 120 Germany.
This study was supported by a research grant from Bristol-Myers Squibb, Munich, Germany. This work was presented in part at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta, Georgia, November 1993.
- Received December 21, 1994.
- Revision received May 16, 1995.
- Accepted May 24, 1995.
- American College of Cardiology